v3.26.1
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Common Share (Details) - Titan Pharmaceuticals Inc [Member] - shares
shares in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,169
Convertible Preferred Stock [Member]    
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount 593
Convertible Notes [Member]    
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount 7
Employee Stock Awards [Member]    
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount 92
Warrant [Member]    
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount 477